Key-protease inhibition regimens promote tumor targeting of neurotensin radioligands

HIGHLIGHTS

• who: Panagiotis Kanellopoulos and colleagues from the Molecular Pharmacology, School of Medicine, University of Crete, Heraklion, Greece have published the research work: Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands, in the Journal: Pharmaceutics 2020, 528 of /2020/
• what: This approach has been largely undermined by the rapid in vivo degradation of linear NT-based radioligands. The authors aim to increase the tumor targeting of three 99m Tc-labeled NT analogs by the in-situ inhibition of two key proteases involved in their catabolism. Herein, the authors compare the biological profile of three . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.